Novel Prognostic Model Based on Immune Signature for Head and Neck Squamous Cell Carcinoma

Abstract EN

Background.

Deciphering the immune characteristics within tumors and identifying the immune signals related to the prognostic factor are helpful for the treatment and management of tumor patients.

However, systematic analysis of immune signatures in head and neck squamous cell carcinoma (HNSCC) remains largely unstudied.

Methods.

A total of 718 immune-related genes were extracted from RNA sequencing data from 519 HNSCC patients in the TCGA database, and survival analysis with integrated bioinformatics analyses was performed to build the final predictive prognosis model.

Results.

The 178 survival-associated genes (P<0.05) participated in important immune functions, including immune cell activation and migration.

Multivariate regression analysis using 93 genes (P<0.01), together with survival-associated clinicopathological parameters, identified 35 independent prognostic factors.

The most significant 8 independent factors were CD3E, CD40LG, TNFRSF4, CD3G, CD5, ITGA2B, ABCB1, and TNFRSF13b.

The final prognostic model achieved outstanding predictive efficiency with the highest AUC of 0.963.

Conclusion.

Our prognostic model based on the immune signature could effectively predict the prognosis of HNSCC patients, providing novel predictive biomarkers and potential therapeutic targets for HNSCC patients.